Screener
McKesson MCK Business Segments
| Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | ||
|---|---|---|---|---|---|---|
| Revenue derived from services (less than) (as a percent) by Business | ||||||
| Medical-Surgical Solutions | 1%0.0pp | —— | 1%0.0pp | 1%0.0pp | 1%0.0pp | |
| North American Pharmaceutical | 1%0.0pp | —— | 1%0.0pp | 1%0.0pp | 1%— | |
| Oncology & Multispecialty | 7%0.0pp | —— | 7%0.0pp | 7%0.0pp | 7%— | |
| Prescription Technology Solutions | 39%0.0pp | 7%0.0pp | 36%0.0pp | 37%0.0pp | 39%+1.0pp | |
| Total long-lived assets by Geography | ||||||
| Foreign | $244M-26.1% | $255M-16.7% | $254M— | $261M— | $330M— | |
| United States | $3.19B+7.9% | $3.18B+10.4% | $3.13B— | $3.1B— | $2.95B— |
FAQ
- How does McKesson break its business down?
- McKesson (MCK) reports revenue derived from services (less than) (as a percent) by business across 4 parts — Medical-Surgical Solutions, North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions. Each is extracted from the segment footnotes and tracked over time.
- Where does McKesson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in McKesson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
